Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Deoxycholic Acid Obesity Drugs Market Growth From $0.57 Billion In 2026 To $0.97 Billion By 2030 At A CAGR Of 14.1%
The deoxycholic acid obesity drugs market has seen rapid expansion over recent years. It is anticipated to increase from $0.5 billion in 2025 to $0.57 billion in 2026, registering a compound annual growth rate (CAGR) of 14.4%. Factors contributing to its historical growth include greater consumer understanding of aesthetic treatments, the proliferation of medical aesthetics clinics, an increasing preference for minimally invasive procedures, the accessibility of approved deoxycholic acid formulations, and a rise in disposable income.
The market size for deoxycholic acid obesity drugs is projected to experience swift expansion over the coming years. It is anticipated to reach $0.97 billion in 2030, showing a compound annual growth rate (CAGR) of 14.1%. This growth during the projected timeframe stems from several factors, including a heightened demand for tailored aesthetic treatments, the broadening of combination aesthetic approaches, an escalating emphasis on body sculpting techniques, increased funding into innovative aesthetic drugs, and deeper market penetration in developing regions. Key trends expected within the forecast period encompass a greater acceptance of non-invasive fat reduction methods, an increasing preference for injectable aesthetic solutions, the evolving creation of combined lipolytic treatments, an increase in clinic-provided body sculpting offerings, and a sharpened attention on aesthetic results customized for each patient.
Get A Free Sample Report With In-Depth Market Insights:
Deoxycholic Acid Obesity Drugs Market Development Factors: What’s Supporting Demand?
The growth of the deoxycholic acid obesity drug market is anticipated to be driven by increasing obesity rates. These rates define the percentage of a population categorized as overweight or obese based on their body mass index (BMI). Poor dietary habits, such as a high intake of processed foods and sugary drinks, contribute to rising obesity by leading to excess calorie storage as body fat. Deoxycholic acid obesity drugs address this by breaking down and eliminating surplus fat cells, achieving targeted fat reduction and an improved body contour. For instance, in May 2025, the Office for Health Improvement and Disparities, a UK-based government body, reported that from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, an increase from 64.0% in 2022 to 2023. This upward trend in obesity rates is consequently propelling the expansion of the deoxycholic acid obesity drug market.
Deoxycholic Acid Obesity Drugs Market Segment Landscape: Which Areas Lead Development?
The deoxycholic acid obesity drugs market covered in this report is segmented –
1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products
2) By Formulation: Injectable, Topical
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
4) By Application: Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management
5) By End-User: Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration
Subsegments:
1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable, High-Purity Formulations, Combination Injection Therapies
2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations, Compounded Customized Formulations
3) By Combination Therapies: Deoxycholic Acid + Lipolytic Agents, Deoxycholic Acid + Enzyme Therapy
4) By Oral Deoxycholic Acid Products: Capsules, Tablets, Liquid Formulations
Deoxycholic Acid Obesity Drugs Market Transformation Trends: What Innovations Are Driving Change?
Prominent companies within the deoxycholic acid obesity drug market are concentrating on creating sophisticated products, including injectable deoxycholic acid obesity drugs, to elevate treatment effectiveness and achieve better patient results. These injectable deoxycholic acid obesity drugs utilize deoxycholic acid, a compound that breaks down fat cells, and are administered via injection to specifically target and diminish fat in particular areas. For instance, in March 2024, LG Chem Ltd., a chemicals company based in South Korea, unveiled Bellacholine, intended for the reduction of submental fat. This is a nonsurgical injection formulated to decrease moderate to severe submental fat (double chin) by safely eliminating fat cells using deoxycholic acid. It provides benefits such as a body-compatible pH, minimal sedimentation, and the encouragement of skin elasticity through collagen synthesis.
Deoxycholic Acid Obesity Drugs Market Industry Leaders And Competitive Landscape
Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A
View The Full Deoxycholic Acid Obesity Drugs Market Report:
Deoxycholic Acid Obesity Drugs Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxycholic acid obesity drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model